KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查

Elacestrant in metastatic breast cancer: Is the "standard of care" meeting standard requirements?

Timothée Olivier, Vinay Prasad

Transl Oncol 15(1) 101273

PMID34798371
PMCIDPMC8605291
DOI10.1016/j.tranon.2021.101273
发表日期2021-11-19
摘要

摘要

The EMERALD trial was an open label phase 3 trial evaluating elacestrant, the first oral selective estrogen receptor degrader (SERD), as compared to "standard of care", in ER+/HER2- (hormone receptor positive, no HER2 overexpression) advanced or metastatic breast cancer. The EMERALD trial restricted the "standard of care" control arm to limited options that may have led to a substandard control arm. We describe how the EMERALD trial protocol allowed different clinically inappropriate scenarios in the control arm, according to prior therapy. The main relevant question remains the potential advantage of elacestrant over fulvestrant in fulvestrant-naive patients. Analyzing outcomes in subgroups according to prior and per-protocol therapy would help analyzing trial results. However, these subgroup results may be non-significant, and another randomized trial will be needed. Trials should be designed to answer directly clinical questions that are relevant.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。